Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients

Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients

Patients with type 2 diabetes and non-alcoholic fatty liver disease will be enrolled.

According to a parallel design, the participants will be randomized to a Portfolio diet or a monounsaturated fatty acid (MUFA)-rich diet (used as control) for 8 weeks.

At the beginning and at the end of the trial, the participants will undergo a MRI spectroscopy to evaluate fatty liver content. Moreover, the participants will undergo a test meal resembling the nutritional composition of the assigned diet to evaluate fasting and postprandial metabolic response.

Inclusion Criteria:

• type 2 diabetes
• non-alcoholic fatty liver disease (evaluated by US)
• HbA1c <7.5%
• LDL cholesterol <130 mg/dl

Exclusion Criteria:

• hypoglycemic therapy with sodium-glucose cotransporter (SGLT-2), pioglitazone and glucagon-like peptide (GLP-1) analogues
• severe liver and kidney failure
• recent cardiovascular events (prior 6 months)
• any other acute/chronic disease (anemia, cancer, BPCO)